8-K: Corbus CRB-913 Shows Weight Loss, Favorable Safety in Phase 1a

Corbus Pharmaceuticals announced positive Phase 1a data for its obesity drug CRB-913, demonstrating a favorable safety profile and early evidence of weight loss, alongside updates on its oncology pipeline.

Summary

• Corbus Pharmaceuticals completed its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913, an oral CB1 inverse agonist for chronic obesity management.
• The Phase 1a study showed CRB-913 was safe and well-tolerated across all doses, with no serious treatment-emergent adverse events and minimal GI intolerability (only one case of mild diarrhea).
• Daily neuropsychiatric assessments (CSSRS, PHQ-9, GAD-7) remained stable and negative for all participants, with no reported cases of suicidality, depression, or insomnia.
• In the dedicated obese MAD cohort (150 mg QD), CRB-913-treated participants (n=9) achieved a mean 2.9% placebo-adjusted weight loss by Day 14, with individual weight loss ranging from 1.3% to 4.3%.
• Weight loss started early and deepened over time, and several participants reported reduced food-related thoughts and cravings.
• A Phase 1b dose-range finding study (CANYON-1) for CRB-913, involving 240 obese, non-diabetic participants, has been initiated with completion expected in summer 2026.
• The company also provided updates on its oncology pipeline, including CRB-701 (Nectin-4 targeting ADC) with favorable safety and efficacy signals in HNSCC, cervical, and bladder cancers, and CRB-601 (anti-integrin mAb) which recently dosed its first patient.
• Corbus reported $173 million in cash, cash equivalents, and investments as of November 3, 2025, with approximately 17.6 million common shares issued and outstanding.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for CRB-913, particularly its favorable safety profile and early efficacy signals in obesity, addressing a major historical hurdle for this drug class. The oncology pipeline, especially CRB-701, also shows competitive safety and efficacy compared to peers. The initiation of next-phase studies for CRB-913 and ongoing progress for CRB-701 and CRB-601 indicate robust pipeline advancement. The financial position with $173M cash provides a solid runway for continued development.

Positives

• CRB-913 demonstrated a favorable safety and tolerability profile in its Phase 1a study, with no serious treatment-emergent adverse events and minimal GI issues, addressing a key historical challenge for CB1 inverse agonists.
• Neuropsychiatric assessments for CRB-913 remained stable and negative across all participants and time points, indicating a potentially class-leading safety profile in this regard.
• CRB-913 showed early evidence of efficacy, with a mean 2.9% placebo-adjusted weight loss by Day 14 in the obese MAD cohort, and participants reporting reduced food-related thoughts and cravings.
• The pharmacokinetic (PK) profile of CRB-913 supports once-daily oral dosing, enhancing patient convenience.
• Initiation of the Phase 1b CANYON-1 study for CRB-913 marks significant progress towards further clinical development in obesity.
• CRB-701, a next-generation Nectin-4 targeting ADC, showed a favorable emerging safety profile compared to Nectin-4-MMAE peers, with lower rates of Grade 3 adverse events and best-in-class peripheral neuropathy rates.
• CRB-701 demonstrated promising efficacy in HNSCC (ORR 47.6% at 3.6 mg/kg), cervical cancer (ORR 37.5% at 3.6 mg/kg), and bladder cancer (ORR 55.6% at 3.6 mg/kg), comparing favorably to existing treatments like Petosemtamab, Tivdak, and PADCEV.
• CRB-701 has been granted FDA Fast Track Designation for HNSCC and cervical cancer, potentially accelerating its development and review process.
• The company has a diversified pipeline with three drug candidates progressing, including CRB-601 which recently dosed its first patient.

Negatives

• Three adverse events of mild anxiety and one of mild irritability were reported in the obese MAD cohort at 150 mg/day for CRB-913, although these were transient and resolved without intervention.
• Corbus is not currently pursuing metastatic urothelial cancer (mUC) as a stand-alone indication for CRB-701 due to the competitive landscape dominated by Keytruda + PADCEV.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from projections.
• Future clinical trials of CRB-701, CRB-913, or CRB-601 may not reproduce, validate, or otherwise confirm observations from earlier studies.
• The company's ability to successfully develop and commercialize its product candidates is dependent on obtaining regulatory approvals and market acceptance.
• Competition from other pharmaceutical companies developing treatments for oncology and obesity could impact market share and profitability.

Future Outlook

Corbus Pharmaceuticals anticipates completing the CRB-913 Phase 1b CANYON-1 study by summer 2026. For CRB-701, a monotherapy update and registrational pathway update are expected in Q1 2026, with registrational studies planned to start mid-2026 and CRB-701 + pembrolizumab data expected in the second half of 2026. CRB-601 Phase 1/2 monotherapy data is also anticipated by mid-2026.

Management Comments

• Yuval Cohen, PhD, Chief Executive Officer of Corbus, stated, 'We are pleased by the translation of CRB-913 from pre-clinical models to the clinical setting.'
• Yuval Cohen also commented, 'We are encouraged by CRB-913’s potentially class-leading safety and tolerability profile demonstrated in this study.'
• Yuval Cohen noted, 'CRB-913’s observed weight loss effect provides further evidence that a markedly peripherally restricted CB1 inverse agonist could offer an attractive orthogonal monotherapy for obesity or combinatory mode of action to the incretin-pathway therapies.'

Industry Context

The announcement positions CRB-913 as a next-generation CB1 inverse agonist designed to overcome the neuropsychiatric adverse events that led to the abandonment of first-generation drugs like Rimonabant. Its peripherally restricted nature aims to provide a safer alternative for obesity management, potentially as a monotherapy or in combination with incretin-pathway therapies. In oncology, CRB-701 is presented as an improved Nectin-4 targeting ADC, aiming to differentiate itself from existing treatments like PADCEV and Tivdak by offering a better safety profile and competitive efficacy in Nectin-4 positive solid tumors, particularly in HNSCC and cervical cancer where it has received Fast Track Designation.

Comparison to Industry Standards

• CRB-913's Phase 1a data showed a mean 2.9% placebo-adjusted weight loss by Day 14, which compares favorably to early data from other CB1 inverse agonists; for instance, Monlunabant (25 mg) showed approximately 1.5% weight loss at 2 weeks, and Orfoglipron (45 mg QD) showed 3% weight loss at Day 28.
• CRB-913 demonstrated a differentiated and favorable GI tolerability profile compared to Monlunabant, which reported nausea rates of 36%-50% and diarrhea rates of 25%-37%, whereas CRB-913 had no nausea and only one case of mild diarrhea.
• CRB-913's neuropsychiatric safety profile, with negative assessments for suicidality, depression, and insomnia, is a significant improvement over first-generation CB1 inverse agonists like Rimonabant and Monlunabant, which had high rates of psychiatric adverse events and led to their withdrawal or rejection.
• CRB-701 exhibited a lower Grade 3 AE rate (35.5% at 3.6mg/kg) compared to PADCEV (62.5%) and BT8009 (53%) in Nectin-4-MMAE peers.
• CRB-701 showed a best-in-class peripheral neuropathy rate of 8.4% (all Grade 1 or 2) compared to PADCEV (48%) and BT8009 (36%).
• In 2L HNSCC, CRB-701's ORR of 47.6% (at 3.6mg/kg) compares favorably to Petosemtamab (ORR 36%) and PADCEV (ORR 23.9%).
• In 2L cervical cancer, CRB-701's ORR of 37.5% (at 3.6mg/kg) is significantly higher than Tivdak's ORR of 17.8%.
• In 2L bladder cancer, CRB-701's ORR of 55.6% (at 3.6mg/kg) is higher than PADCEV's ORR of 44%.

Stakeholder Impact

• Shareholders: Positive clinical data and pipeline progression could lead to increased investor confidence and potential share price appreciation.
• Patients: The development of CRB-913 offers a potential new, safer treatment option for chronic obesity, while CRB-701 and CRB-601 could provide improved therapies for various cancers.
• Employees: Continued positive clinical development supports job security and potential growth opportunities within the company.
• Regulatory Authorities: The favorable safety profile of CRB-913, particularly regarding neuropsychiatric effects, may be viewed positively by regulatory bodies, potentially streamlining future approvals.

Next Steps

• Complete CRB-913 Phase 1b CANYON-1 study by summer 2026.
• Provide CRB-701 monotherapy update in Q1 2026.
• Provide CRB-701 registrational pathway update following FDA engagement in Q1 2026.
• Start CRB-701 registrational studies in mid-2026.
• Present CRB-601 Phase 1/2 monotherapy data in mid-2026.
• Present CRB-701 + pembrolizumab data in the second half of 2026.

Key Dates

Recommendation

The filing provides compelling positive clinical data for CRB-913, demonstrating a strong safety profile that addresses historical concerns for CB1 inverse agonists, coupled with promising early weight loss efficacy. This significantly de-risks the program and opens a large market opportunity. Additionally, CRB-701 shows competitive efficacy and a superior safety profile compared to existing Nectin-4 ADCs in multiple oncology indications, with FDA Fast Track designation. The company's diversified pipeline and solid cash position further support a positive outlook, making it an attractive investment for growth-oriented investors.

Keywords

Corbus Pharmaceuticals, CRBP, obesity, CB1 inverse agonist, CRB-913, oncology, Nectin-4 ADC, CRB-701, anti-integrin mAb, CRB-601, clinical trial, Phase 1a, Phase 1b, CANYON-1, weight loss, safety, tolerability, pharmacokinetics, HNSCC, cervical cancer, bladder cancer, drug development, biotechnology